Filing Details
- Accession Number:
- 0001628280-25-007532
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-24 20:20:14
- Reporting Period:
- 2025-02-21
- Filing Date:
- 2025-02-24
- Accepted Time:
- 2025-02-24 20:20:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1356576 | Supernus Pharmaceuticals Inc. | SUPN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1836067 | Jonathan Rubin | C/O Supernus Pharmaceuticals, Inc., 9715 Key West Avenue Rockville MD 20850 | Svp, Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-02-21 | 1,875 | $0.00 | 8,780 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-21 | 927 | $39.15 | 7,853 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-02-22 | 750 | $0.00 | 8,603 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2025-02-22 | 1,250 | $0.00 | 9,853 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2025-02-23 | 1,250 | $0.00 | 11,103 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance Share Units | Disposition | 2025-02-21 | 1,875 | $0.00 | 1,875 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2025-02-22 | 750 | $0.00 | 750 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2025-02-22 | 1,250 | $0.00 | 1,250 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2025-02-23 | 1,250 | $0.00 | 1,250 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct | ||
| 750 | No | 4 | D | Direct | ||
| 3,750 | No | 4 | D | Direct | ||
| 2,500 | No | 4 | D | Direct |
Footnotes
- Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024.
- Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
- On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.
- Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023.
- These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
- These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
Billionaire Hedge Funds
